NO319830B1 - Fremgangsmate for krystallisering av N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4-karboksamid - Google Patents

Fremgangsmate for krystallisering av N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4-karboksamid Download PDF

Info

Publication number
NO319830B1
NO319830B1 NO20014077A NO20014077A NO319830B1 NO 319830 B1 NO319830 B1 NO 319830B1 NO 20014077 A NO20014077 A NO 20014077A NO 20014077 A NO20014077 A NO 20014077A NO 319830 B1 NO319830 B1 NO 319830B1
Authority
NO
Norway
Prior art keywords
mol
compound
water
formula
amount
Prior art date
Application number
NO20014077A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014077D0 (no
NO20014077L (no
Inventor
Hans-Hermann Lau
Udo Hedtmann
Holger Faasch
Andreas Gappisch
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20014077D0 publication Critical patent/NO20014077D0/no
Publication of NO20014077L publication Critical patent/NO20014077L/no
Publication of NO319830B1 publication Critical patent/NO319830B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20014077A 1999-02-26 2001-08-22 Fremgangsmate for krystallisering av N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4-karboksamid NO319830B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19908527A DE19908527C2 (de) 1999-02-26 1999-02-26 Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
PCT/EP2000/001151 WO2000050411A1 (de) 1999-02-26 2000-02-12 Verfahren zur kristallisation von n- (4-trifluormethylphenyl) -5-methyl- isoxazol- 4-carboxamid

Publications (3)

Publication Number Publication Date
NO20014077D0 NO20014077D0 (no) 2001-08-22
NO20014077L NO20014077L (no) 2001-10-24
NO319830B1 true NO319830B1 (no) 2005-09-19

Family

ID=7899073

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014077A NO319830B1 (no) 1999-02-26 2001-08-22 Fremgangsmate for krystallisering av N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4-karboksamid

Country Status (22)

Country Link
US (1) US6303792B1 (es)
EP (1) EP1155004B1 (es)
JP (1) JP4625187B2 (es)
KR (1) KR100626110B1 (es)
CN (1) CN1127491C (es)
AR (1) AR022737A1 (es)
AT (1) ATE257828T1 (es)
AU (1) AU762394B2 (es)
BR (1) BR0008566B1 (es)
CA (1) CA2363875C (es)
DE (2) DE19908527C2 (es)
DK (1) DK1155004T3 (es)
ES (1) ES2214259T3 (es)
HK (1) HK1043787B (es)
HU (1) HU228918B1 (es)
IL (2) IL144867A0 (es)
NO (1) NO319830B1 (es)
NZ (1) NZ513777A (es)
PL (1) PL199365B1 (es)
PT (1) PT1155004E (es)
WO (1) WO2000050411A1 (es)
ZA (1) ZA200106973B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19610955A1 (de) * 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
KR20020067545A (ko) * 1999-12-16 2002-08-22 테바 파마슈티컬 인더스트리즈 리미티드 레플루노마이드의 신규 제조 방법 및 이의 신규 결정형
PL366088A1 (en) * 2000-02-15 2005-01-24 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
CN107311954B (zh) * 2017-05-17 2020-04-07 力赛生物医药科技(厦门)有限公司 来氟米特晶型化合物、制备方法及其应用
CN114436894A (zh) * 2020-11-04 2022-05-06 欣凯医药化工中间体(上海)有限公司 泰瑞米特钠晶型及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
HU222234B1 (hu) * 1990-05-18 2003-05-28 Aventis Pharma Deutschland Gmbh. Eljárás izoxazol-4-karbonsav-amidok és hidroxi-alkilidén-cián-ecetsav-amidok, a vegyületeket tartalmazó gyógyászati készítmények és az ismert vegyületeket tartalmazó rákellenes hatású gyógyszerkészítmények előállítására
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
ATE207065T1 (de) 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
DE19734438A1 (de) * 1997-08-08 1999-02-11 Hoechst Marion Roussel De Gmbh Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Also Published As

Publication number Publication date
IL144867A0 (en) 2002-06-30
HUP0200058A3 (en) 2004-07-28
JP4625187B2 (ja) 2011-02-02
KR20010103774A (ko) 2001-11-23
HU228918B1 (en) 2013-06-28
WO2000050411A1 (de) 2000-08-31
IL144867A (en) 2006-12-31
HK1043787A1 (en) 2002-09-27
US6303792B1 (en) 2001-10-16
NO20014077D0 (no) 2001-08-22
BR0008566B1 (pt) 2011-03-22
DE19908527A1 (de) 2000-08-31
EP1155004A1 (de) 2001-11-21
AU762394B2 (en) 2003-06-26
DE19908527C2 (de) 2001-08-30
CA2363875A1 (en) 2000-08-31
AU3803800A (en) 2000-09-14
CN1127491C (zh) 2003-11-12
EP1155004B1 (de) 2004-01-14
ZA200106973B (en) 2002-08-22
PT1155004E (pt) 2004-05-31
CA2363875C (en) 2008-04-29
AR022737A1 (es) 2002-09-04
KR100626110B1 (ko) 2006-09-20
NZ513777A (en) 2004-01-30
PL350422A1 (en) 2002-12-16
BR0008566A (pt) 2002-01-22
HK1043787B (zh) 2004-03-05
PL199365B1 (pl) 2008-09-30
NO20014077L (no) 2001-10-24
DE50005025D1 (de) 2004-02-19
JP2002537388A (ja) 2002-11-05
CN1341106A (zh) 2002-03-20
DK1155004T3 (da) 2004-04-13
ATE257828T1 (de) 2004-01-15
ES2214259T3 (es) 2004-09-16
HUP0200058A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
EP1904448B1 (en) Purification of montelukast
US20090209567A1 (en) Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
EP1513846B1 (en) Process of preparation of olanzapine form i
CN112638885B (zh) 一种缬沙坦的合成方法
NO319830B1 (no) Fremgangsmate for krystallisering av N-(4-trifluormetylfenyl)-5-metyl-isoksazol-4-karboksamid
US6884888B2 (en) Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon)
Bowler et al. Synthesis of agonists and antagonists for central glutamate receptors by a novel ‘ring switching’strategy1
AU755699B2 (en) A reference compound for use in the analysis of levosimendan batches
US20060128788A1 (en) Purification of tegaserod maleate
US20220298124A1 (en) Process for the preparation of clc-1 chloride channel inhibitors
JP4510614B2 (ja) 光学活性β−アミノケトン、光学活性1,3−アミノアルコール、およびそれらの製造方法
MXPA01008494A (es) Proceso para cristalizar n-(4-trifluorometilfenil)-5-metilisoxazol-4-carboxamida
KR20160030972A (ko) 피리미딘 중간체의 제조 방법
NO318781B1 (no) Fremgangsmate til fremstilling av et 3(2H)-pyridazinon-4-substituert amino-5-klorderivat
NO177855B (no) Fremgangsmåte for fremstilling av synergistiner
NO153651B (no) Fremgangsmaate for isomeriseing av derivater av 3-vinylpiperidin.
EP3972961B1 (en) Method for preparation of carsalam
JPH07291933A (ja) 2,5−二置換ピリジン類の製造方法
AU2005298824B2 (en) A process for the preparation of [1,4,5]-oxadiazepane derivatives
SU1553528A1 (ru) Способ получени полизамещенных бензолов
CN111574502A (zh) 一种咔唑类荧光衍生试剂的设计合成及其在氟虫腈和氟虫腈代谢物检测中的应用
JPH0699382B2 (ja) N−メチル−α−ジアルキルアミノアセトヒドロキサム酸誘導体
Buckley et al. The synthesis of deuterium‐labelled propantheline bromide
CN110256264A (zh) 一种美金刚甘氨酸的合成方法
HU193554B (en) Process for producing 1,5,10-triaza-decane derivatives protected at the 1- and 5-positions

Legal Events

Date Code Title Description
MK1K Patent expired